mofezolac has been researched along with Multiple Myeloma in 1 studies
mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pati, ML | 1 |
| Vitale, P | 1 |
| Ferorelli, S | 1 |
| Iaselli, M | 1 |
| Miciaccia, M | 1 |
| Boccarelli, A | 1 |
| Di Mauro, GD | 1 |
| Fortuna, CG | 1 |
| Souza Domingos, TF | 1 |
| Rodrigues Pereira da Silva, LC | 1 |
| de Pádula, M | 1 |
| Cabral, LM | 1 |
| Sathler, PC | 1 |
| Vacca, A | 1 |
| Scilimati, A | 1 |
| Perrone, MG | 1 |
1 other study available for mofezolac and Multiple Myeloma
| Article | Year |
|---|---|
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Ce | 2019 |